Cited by 88Cardiac Valve Diseases and TreatmentsAortic Disease and Treatment ApproachesInfective Endocarditis Diagnosis and Management

Comprehensive Analysis of Mortality Among Patients Undergoing TAVR

Open access
Svensson, Lars G., Blackstone, Eugene H., Rajeswaran, Jeevanantham, Brozzi, Nicholas, Leon, Martin B., Smith, Craig R., Mack, Michael, Miller, D. Craig +17 more·2014·Journal of the American College of Cardiology

Abstract

Background Patients with severe aortic stenosis (AS) who were deemed too high risk or inoperable for conventional aortic valve replacement (AVR) in the PARTNER (Placement of Aortic Transcatheter Valves) trial were randomized to transcatheter aortic valve replacement (TAVR) versus AVR (PARTNER-A arm) or standard therapy (PARTNER-B arm).Objectives This study compared when and how deaths occurred after TAVR versus surgical AVR or standard therapy.Methods The PARTNER-A arm included 244 transfemoral (TF) and 104 transapical (TA) TAVR patients, and 351 AVR patients; the PARTNER-B arm included 179 TF-TAVR patients and 179 standard therapy patients. Deaths were categorized as cardiovascular, noncardiovascular, or uncategorizable, and were characterized by multiphase hazard modelling.Results In the PARTNER-A arm, the risk of death peaked after randomization in the TA-TAVR and AVR groups, falling to low levels commensurate with the U.S. population within 3 months. Early risk was less in TF-TAVR patients, resulting in initial superior survival; between 12 and 18 months, risk increased, such that within 2 years, TF-TAVR and AVR patients had similar survival rates. Cardiovascular, noncardiovascular, and uncategorizable deaths for TF-TAVR were 37%, 43%, and 20%, respectively, versus 22%, 41%, and 37%, respectively, for TA-TAVR and 33%, 43%, and 24%, respectively, for AVR. In the PARTNER-B arm, risk with standard therapy was 60% per year; TF-TAVR reduced risk to 20% per year, resulting in 0.5 years of life added within 2.5 years.Conclusions In inoperable AS patients, TAVR substantially reduced the risk of cardiovascular death. In high-risk patients, TA-TAVR and AVR were associated with elevated peri-procedural risk more than with TF-TAVR, although cardiovascular death was higher after TF-TAVR. Therefore, TF-TAVR should be considered the standard of care for severely symptomatic inoperable patients or those at high risk of noncardiovascular mortality after conventional surgery. (THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2013.08.1666

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • When cause of death was difficult to categorize, it often occurred in frail patients who were failing to thrive.

    “Moreover, when cause of death was difficult to categorize, it often occurred in frail patients who were failing to thrive246.”

    From Calcific aortic stenosis (2016) · cites this paper as [246]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [3]3. Webb JG, Altwegg L, Boone RH, et al. Trans- catheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation 2009;119:3009-16.

Cited by

Sorted by citations

Authors
Svensson, L. G., Blackstone, E. H., Rajeswaran, J., Brozzi, N., Leon, M. B., Smith, C. R., Mack, M., Miller, D. C., Moses, J. W., Tuzcu, E. M., Webb, J. G., Kapadia, S., Fontana, G. P., Makkar, R. R., Brown, D. L., Block, P. C., Guyton, R. A., Thourani, V. H., Pichard, A. D., Bavaria, J. E., Herrmann, H. C., Williams, M. R., Babaliaros, V., Généreux, P., & Akin, J. J.
Affiliations
  • Cleveland Clinic (US)
  • NewYork–Presbyterian Hospital (US)
  • Baylor Scott & White Health (US)
  • Stanford Medicine (US)
  • University of British Columbia (CA)
  • Cedars-Sinai Medical Center (US)
  • Emory University (US)
  • MedStar Washington Hospital Center (US)
  • Hospital of the University of Pennsylvania (US)
  • Edwards Lifesciences (United States) (US)
Corresponding author
Svensson, Lars G.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2014-07
Volume
64
Issue
2
Pages
158-168
ISSN
0735-1097 (ISSN-L)
OpenAlex
W154700364
Cited by
88
References
32
Citations by year
2026: 2 · 2025: 4 · 2024: 1 · 2023: 6 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 4 · 2017: 13 · 2016: 18 · 2015: 15 · 2014: 4
FWCI
11.45
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Edwards Lifesciences
  • Boston Scientific Corporation
  • St. Jude Medical
  • Abbott Vascular
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Aortic Disease and Treatment Approaches
  • Health Sciences › Medicine › Epidemiology › Infective Endocarditis Diagnosis and Management
Keywords
transcatheter aortic valve implantation, severe aortic stenosis, mortality, cardiovascular mortality, transfemoral access, transapical approach, surgical aortic valve replacement, PARTNER trial, inoperable patients, high-risk patients, survival analysis, standard therapy comparison, timing of death
MeSH terms
Aged, Aortic Valve Stenosis, Cause of Death, Female, Follow-Up Studies, Cardiac Catheterization, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, Severity of Illness Index, Time Factors, United States, Survival Rate, Treatment Outcome, Risk Assessment, Heart Valve Prosthesis Implantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review